The manufacturer of off-patent branded pharmaceuticals is continuing its active M&A strategy. As Dermapharm recently announced, the acquisition of the French market leader for herbal medicines and dietary supplements called Apharma Topco is planned. This is the holding company of the Arkopharma Group.

Dermapharm, one of the producers of BioNTech’s corona vaccine, wants to buy the French company for a purchase price of around 450 million euros. If all approvals are in place, the transaction could be completed in early January 2023.